Tdam USA Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 237,246 shares of the company’s stock after selling 13,369 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Tdam USA Inc.’s investment portfolio, making the stock its 6th biggest position. Tdam USA Inc.’s holdings in Johnson & Johnson were worth $28,788,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Financial Gravity Wealth Inc. purchased a new position in Johnson & Johnson in the first quarter valued at $105,000. WP Advisors LLC purchased a new position in Johnson & Johnson in the second quarter valued at $108,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson in the second quarter valued at $117,000. Live Your Vision LLC increased its holdings in Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares during the last quarter. Finally, Signition LP purchased a new position in Johnson & Johnson in the first quarter valued at $204,000. Institutional investors and hedge funds own 66.60% of the company’s stock.
Several research firms recently commented on JNJ. Citigroup increased their target price on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Credit Suisse Group increased their target price on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Raymond James increased their target price on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $142.54.
Shares of JNJ stock opened at $145.30 on Friday. The stock has a market cap of $382.50 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 2.23 and a beta of 0.58. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.90 earnings per share. Analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.
COPYRIGHT VIOLATION NOTICE: This report was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.wkrb13.com/2018/11/09/johnson-johnson-jnj-shares-sold-by-tdam-usa-inc.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What is a conference call?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.